Phase 1 Three Period Crossover Study To Evaluate The Effect Of Food And Antacids On The Pharmacokinetics, Safety and Tolerability Of PF-299,804 In Healthy Volunteers Who Have Received PF-299 804
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2014
At a glance
- Drugs Dacomitinib (Primary) ; Rabeprazole
- Indications Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 04 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.